Date: 2013-03-26
Type of information: Services contract
Compound: homologous recombination deficiency (HRD) testing
Company: Myriad Genetics (USA) PharmaMar (Spain)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
services
Action mechanism: Myriad\'s HRD test is able to detect when a tumor has lost the ability to repair DNA damage and would therefore be more susceptible to the DNA-damaging classes of drugs. The test directly measures the end result of the loss of the DNA repair function regardless of the genomic causation. The HRD test is effective at detecting the loss of function irrespective of whether the defects in the genes involved in the DNA repair mechanism were caused by hereditary germ line mutations or somatic mutations accumulated during the patient\'s life. Myriad\'s HRD test has been shown to accurately predict drug response in both ovarian cancer patients and triple negative breast cancer patients.
Disease:
Details: Myriad Genetics has signed an agreement with PharmaMar, a spanish company dedicated to the development of marine-derived drugs. Under the terms of the agreement, Myriad will conduct homologous recombination deficiency (HRD) testing on patients enrolled in PharmaMar's Phase II clinical study of PM1183, a novel drug candidate which induces double-stranded DNA breaks to cause cell death. This partnership represents Myriad Genetics\' first publicly announced commercial collaboration with its new HRD test.
Under the terms of the agreement, Myriad will assess HRD status in patients who have been treated with PM1183 in PharmaMar\'s Phase II clinical study. Utilizing this information, Myriad and PharmaMar will hope to garner more information surrounding the role of HRD status in PM1183 response.
Financial terms:
Latest news:
